摘要
目的分析孟鲁司特钠联合酮替芬治疗小儿喘息性支气管炎的临床疗效。方法98例小儿喘息性支气管炎患儿,依据随机数字表法分为研究组与对照组,各49例。对照组采取孟鲁司特钠治疗,研究组采取孟鲁司特钠联合酮替芬治疗。对比两组治疗前后外周血嗜酸性粒细胞计数(EOS)及免疫球蛋白E(IgE)水平、免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、炎性因子[白细胞三烯E4(LTE4)、白细胞介素(IL)-10、嗜酸性粒细胞阳离子蛋白(ECP)]水平、症状消失时间、不良反应发生情况。结果治疗后,研究组EOS(0.31±0.07)×109/L、IgE(103.62±26.19)IU/ml均低于对照组的(0.42±0.09)×109/L、(166.49±22.63)IU/ml,差异有统计学意义(P<0.05)。治疗后,研究组患儿干湿啰音、咳嗽、发热、肺部鸣音消失时间分别为(3.29±0.26)、(3.01±0.21)、(2.29±0.18)、(2.54±0.23)d,均短于对照组的(4.12±0.53)、(3.17±0.42)、(3.85±0.46)、(2.89±0.42)d,差异有统计学意义(P<0.05)。治疗后,研究组CD4^(+)(33.65±3.27)%、CD4^(+)/CD8^(+)(1.86±0.25)高于对照组的(31.19±3.15)%、(1.69±0.21),差异有统计学意义(P<0.05)。治疗后,研究组LTE4(36.47±1.24)pg/L、IL-10(8.65±1.05)pg/L、ECP(8.36±1.11)μg/L均低于对照组的(78.48±1.29)pg/L、(12.74±1.15)pg/L、(14.65±1.12)μg/L,差异有统计学意义(P<0.05)。治疗后,研究组不良反应发生率4.08%低于对照组的18.37%,差异有统计学意义(P<0.05)。结论孟鲁司特钠联合酮替芬治疗小儿喘息性支气管炎疗效显著,可有效缓解临床症状,促进患儿免疫功能增强,降低不良反应发生几率,具有较高的安全性,值得临床推广使用。
Objective To analyze the clinical efficacy of montelukast sodium combined with ketotifen in the treatment of asthmatic bronchitis in children.Methods A total of 98 children with asthmatic bronchitis were divided into research group and control group according to the random numerical table,with 49 cases in each group.The control group was treated with montelukast sodium,and the research group was treated with montelukast sodium and ketotifen.Both groups were compared in terms of eosinophil count(EOS)and immunoglobulin E(IgE)levels,immune function indicators(CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),inflammatory factors[leukotriene E4(LTE4),interleukin(IL)-10,eosinophil cationic protein(ECP)]levels before and after treatment,symptom disappearance time,and occurrence of adverse reactions.Results After treatment,the EOS(0.31±0.07)×10~9/L and IgE(103.62±26.19)IU/ml in the research group were lower than(0.42±0.09)×10~9/L and(166.49±22.63)IU/ml in the control group,and the differences were statistically significant(P<0.05).After treatment,the disappearance time of dry and wet rales,cough,fever,and pulmonary sounds in the research group were(3.29±0.26),(3.01±0.21),(2.29±0.18),and(2.54±0.23)d,which were shorter than(4.12±0.53),(3.17±0.42),(3.85±0.46),and(2.89±0.42)d in the control group,and the differences were statistically significant(P<0.05).After treatment,the CD4^(+)(33.65±3.27)%and CD4^(+)/CD8^(+)(1.86±0.25)in the research group were higher than(31.19±3.15)%and(1.69±0.21)in the control group,and the differences were statistically significant(P<0.05).After treatment,the LTE4(36.47±1.24)pg/L,IL-10(8.65±1.05)pg/L,and ECP(8.36±1.11)μg/L in the research group were lower than(78.48±1.29)pg/L,(12.74±1.15)pg/L,and(14.65±1.12)μg/L in the control group,and the differences were statistically significant(P<0.05).After treatment,the incidence of adverse reactions in the research group was 4.08%,which was lower than 18.37%in the control group,and the difference was statistically significant(P<0.05).Conclusion Montelukast sodium combined with ketotifen has significant efficacy in the treatment of asthmatic bronchitis in children,and can effectively relieve clinical symptoms,promote the enhancement of immune function of patients and reduce the chance of adverse reactions.It has high safety,and is worthy of clinical promotion and application.
作者
曲新栋
吕艳
QU Xin-dong;LYU Yan(Department of Pediatrics,Second Weihai Municipal Hospital Affiliated to Qingdao University,Weihai 264200,China)
出处
《中国实用医药》
2023年第3期36-39,共4页
China Practical Medicine
关键词
孟鲁司特钠
酮替芬
小儿喘息性支气管炎
临床疗效
Montelukast sodium
Ketotifen
Asthmatic bronchitis in children
Clinical efficacy
